Krebs Biochemicals and Industries Limited — Board Meeting, 20-05-2025: Outcome of Board Meeting

Krebs Biochemicals & Industries Limited has announced a board meeting on which approved the financial results for the quarter and half-year. Total income fell to Rs. 44.02 Cr from Rs. 50.87 Cr year-on-year. The consolidated loss widened to Rs. 26.93 Cr versus Rs. 19.75 Cr previously. EBITDA remains weak, with finance costs rising to Rs. 5.91 Cr. Negative net worth stands at Rs. 146.24 Cr, and operating cash flow is under pressure at -Rs. 7.89 Cr, signaling continued operational challenges despite clean audit feedback.